Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.

about

Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.

Item

http://www.wikidata.org/entity/Q47191075

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Tofacitinib with conventional ...... 3 randomized controlled trial.

@en

Tofacitinib with conventional ...... 3 randomized controlled trial.

@nl

type

Item

label

Tofacitinib with conventional ...... 3 randomized controlled trial.

@en

Tofacitinib with conventional ...... 3 randomized controlled trial.

@nl

prefLabel

Tofacitinib with conventional ...... 3 randomized controlled trial.

@en

Tofacitinib with conventional ...... 3 randomized controlled trial.

@nl

P1476

Tofacitinib with conventional ...... 3 randomized controlled trial.

@en

P2093

Guiye Li

http://www.w3.org/2001/XMLSchema#string

Houheng Su

http://www.w3.org/2001/XMLSchema#string

Jianhua Xu

http://www.w3.org/2001/XMLSchema#string

Kenneth Kwok

http://www.w3.org/2001/XMLSchema#string

Lisy Wang

http://www.w3.org/2001/XMLSchema#string

Qizhe Wu

http://www.w3.org/2001/XMLSchema#string

Xiangpei Li

http://www.w3.org/2001/XMLSchema#string

Yi Zheng

http://www.w3.org/2001/XMLSchema#string

Yuan An

http://www.w3.org/2001/XMLSchema#string

Zhanguo Li

http://www.w3.org/2001/XMLSchema#string

P2860

The MOS 36-ltem Short-Form Health Survey (SF-36)

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DA

Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

P304

402-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1756-185X.13244

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29314645

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5817244

http://www.w3.org/2001/XMLSchema#string